Monitoring urine proteins to predict early recurrence of liver cancer after surgery
Exploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepatocellular Carcinoma: a Prospective Cohort Study
This study is testing if checking urine proteins can help doctors spot early signs of liver cancer coming back after surgery, so they can start treatment sooner for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 38 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Zhujiang Hospital Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06861114 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of urine proteomics to monitor patients after radical surgery for hepatocellular carcinoma (HCC) to predict early recurrence of the disease. It aims to validate a model that assesses minimal residual disease (MRD) status through urine samples, potentially identifying recurrences sooner than traditional imaging methods. The study also explores the feasibility of using these findings to guide adjuvant treatment strategies in the postoperative period, offering a novel approach to early intervention for HCC patients.
Who should consider this trial
Good fit: Ideal candidates are patients with hepatocellular carcinoma at BCLC staging 0, A, or B who are eligible for radical surgical resection and have not undergone prior antitumor therapy.
Not a fit: Patients with renal or urologic diseases, multiple tumors, or those who have previously received anti-tumor therapies may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection of liver cancer recurrence, allowing for timely interventions that may improve patient outcomes.
How similar studies have performed: While the use of urine proteomics in cancer monitoring is an emerging field, this specific approach to HCC recurrence is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with hepatocellular carcinoma whose tumor stage at the time of initial diagnosis is consistent with BCLC staging 0/stage A/stage B, who can undergo radical surgical resection, and who have not received other antitumor therapy preoperatively. Exclusion Criteria: * Unable to provide specimens for testing such as urine proteomics; patients with a previous diagnosis of renal or urologic disease, two or more tumors at the same time; patients with non-primary foci of liver disease. Previously received anti-tumor therapy such as targeted immunotherapy.
Where this trial is running
Guangzhou, Guangdong
- Zhujiang Hospital of Southern Medical University — Guangzhou, Guangdong, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.